PURPOSE: To evaluate the efficacy and tolerability of a combination of @entity1206 (VNR) and @entity1205 ( @entity4420 ) as first-line chemotherapy in @entity1 with metastatic @entity0 . @entity1 AND METHODS: The study group comprised 40 @entity1 with untreated metastatic @entity0 with visceral (85%) and bone (70%) metastases. Of the 40 @entity1 , 24 (60%) had previously received adjuvant chemotherapy, which had included anthracyclines in 12 @entity1 (30%). Treatment consisted of VNR 25 mg/m(2) on days 1 and 5, and @entity4420 75 mg/m(2) on day 1 every 3 weeks. Depending on the neutrophil nadir (grade 3 or 4 @entity1398 by WHO criteria) recombinant @entity1 @entity1261 ( @entity1261 ) 5 micro g/kg on days 2-4 and 6-13 was given for all subsequent treatment cycles. RESULTS: The overall response rate (ORR) was 40% (95% confidence interval, CI 15-65). Six @entity1 (15%) achieved a complete response (CR) and ten @entity1 (25%) achieved a partial response (PR). @entity66 ( @entity66 ) was observed in six @entity1 (15%), and 18 @entity1 (45%) had @entity74 ( @entity74 ). The median duration of response was 8 months and the median predictive @entity1054 ( @entity1054 ) was 6 months. The main @entity137 was @entity1398 grade 3 and 4 in 28 @entity1 (70%). @entity1398 requiring hospitalization occurred in 12 @entity1 (30%). Grade 3 or 4 @entity417 was seen in two @entity1 (5%) and grade 3 or 4 @entity882 was seen in one @entity1 (2.5%). Severe nonhematologic @entity137 , except @entity1665 , was uncommon and included @entity3136 in two @entity1 (5%), @entity391 in two (5%) and @entity294 in one (2.5%). There were no treatment-related @entity204 . CONCLUSIONS: The combination of VNR and @entity4420 at the doses used in this study showed moderate activity as first-line chemotherapy in metastatic @entity0 . @entity1398 was considerable despite @entity1261 administration.

@entity1206 and @entity1205 as first-line chemotherapy in metastatic XXXX .

@entity1 :: ('9606', 'Species') :: ['human', 'patient', 'women', 'patients', 'PATIENTS'] @entity1665 :: ('MESH:D000505', 'Disease') :: ['alopecia'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity3136 :: ('MESH:D013280', 'Disease') :: ['stomatitis'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity1261 :: ('1440', 'Gene') :: ['granulocyte colony-stimulating factor', 'G-CSF'] @entity66 :: ('MESH:D004194', 'Disease') :: ['SD', 'Stable disease'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anemia'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting'] @entity1054 :: ('MESH:D000377', 'Disease') :: ['time to progression', 'TTP'] @entity1206 :: ('MESH:C030852', 'Chemical') :: ['vinorelbine'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['Neutropenia', 'neutropenia', 'Febrile neutropenia'] @entity74 :: ('MESH:D030342', 'Disease') :: ['PD', 'progressive disease'] @entity204 :: ('MESH:D003643', 'Disease') :: ['deaths'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel'] @entity4420 :: ('CHEBI:16973', 'Chemical') :: ['DOC']
@entity0 :: (MESH:D001943,Disease) :: ['breast cancer']
